(Q37761047)

English

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

scientific article published on 26 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

invasive fungal infections

1 reference

based on heuristic

inferred from title

author name string

S H Jang

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

P M Colangelo

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

J V S Gobburu

3

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

language of work or name

0 references

publication date

26 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

88

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

115-119

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Posaconazole: clinical pharmacology and potential for management of fungal infections

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Antifungal drugs: predicting clinical efficacy with pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

21 January 2018

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis and aspergillosis--has the principle been proven?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.64

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2010.64

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37761047&oldid=1726963545"